This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Teva Pharmaceutical (TEVA) and Nuvation Bio (NUVB)

Tipranks - Tipranks - Thu Jun 11, 6:52AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Merit Medical Systems (MMSI), Teva Pharmaceutical (TEVA) and Nuvation Bio (NUVB) with bullish sentiments.

Introducing TipRanks MCP for Agents

Merit Medical Systems (MMSI)

Piper Sandler analyst Jason Bednar maintained a Buy rating on Merit Medical Systems today and set a price target of $96.00. The company’s shares closed last Tuesday at $67.51.

According to TipRanks.com, Bednar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -4.7% and a 40.9% success rate. Bednar covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Solventum Corporation, and Alpha Tau Medical Ltd. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Merit Medical Systems with a $87.50 average price target.

See today’s best-performing stocks on TipRanks >>

Teva Pharmaceutical (TEVA)

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical, with a price target of $42.00. The company’s shares closed last Tuesday at $34.45.

According to TipRanks.com, Amsellem is a 5-star analyst with an average return of 12.5% and a 60.1% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical. ;'>

Currently, the analyst consensus on Teva Pharmaceutical is a Strong Buy with an average price target of $42.11, implying a 25.8% upside from current levels. In a report issued on May 27, Jefferies also maintained a Buy rating on the stock with a $40.00 price target.

Nuvation Bio (NUVB)

In a report released today, Gregory Renza from Truist Financial maintained a Buy rating on Nuvation Bio. The company’s shares closed last Tuesday at $4.93.

According to TipRanks.com, Renza is a 5-star analyst with an average return of 14.8% and a 45.3% success rate. Renza covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Perspective Therapeutics, and Abivax SA Sponsored ADR. ;'>

Currently, the analyst consensus on Nuvation Bio is a Strong Buy with an average price target of $14.40, representing a 183.5% upside. In a report issued on May 26, H.C. Wainwright also reiterated a Buy rating on the stock with a $17.00 price target.

Read More on MMSI:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).